Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2002

Combination of pamidronate and thalidomide in the therapy of treatment-resistantmultiple myeloma.

Wojciech Baran, Hanna Ciepłuch, Andrzej Hellmann

Med Sci Monit 2002; 8(4): PI31-36 :: ID: 420859

Abstract

BACKGROUND: Bisphosphonates inhibit the activity of osteoclasts and demonstrateantitumor effect, involving induction of plasmocyte apoptosis, blocking of angiogenesis, stimulationof Tgd lymphocytes and inhibition of metalloproteinases. Bisphosphonates combined with thalidomide, adrug possessing confirmed anti-myeloma activity, seem to have potential favorable effect in patientswith treatment-resistant multiple myeloma with advanced osteolytic lesions. MATERIAL/METHODS: 13 patientswith treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronateand thalidomide therapy. All the patients underwent detailed clinical and laboratory control once a month.Pamidronate was used at 90 mg i.v. dose administered at 4-week intervals, and thalidomide at doses escalatedfrom 200 mg/d in the first week to 400 mg/d after 3 weeks of the therapy. The mean duration of treatmentwas 12 weeks with a range of 3 to 36 weeks. RESULTS: 7 patients (53%) receiving pamidronate and thalidomidetherapy demonstrated good response involving at least 25% reduction of monoclonal protein levels in comparisonwith baseline. All these patients reported improvement of osteodynia symptoms, and 3 of them - theircomplete regression. 70% patients experienced side effects (dizziness, constipation, somnolence, polyneuropathy)due to thalidomide administration CONCLUSIONS: Good response to combined pamidronate and thalidomidetherapy can be expected in at least 50% of patients with treatment-resistant multiple myeloma with advancedosteolytic lesions.

Keywords: Aged, 80 and over, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Constipation, Diphosphonates, Disorders of Excessive Somnolence, Dizziness, Multiple Myeloma, Myeloma Proteins, Osteolysis, Pain, Remission Induction, thalidomide

Add Comment 0 Comments

Editorial

01 April 2024 : Editorial  

Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance

Dinah V. Parums

DOI: 10.12659/MSM.944600

Med Sci Monit 2024; 30:e944600

0:00

In Press

04 Mar 2024 : Clinical Research  

Injury-Admission Time is an Independent Risk Factor for Deep Vein Thrombosis in Older Patients with Osteopo...

Med Sci Monit In Press; DOI: 10.12659/MSM.943587  

0:00

04 Mar 2024 : Clinical Research  

Evaluation of the Interrater Reliability of Sonographic Measurements of Muscle Thickness of 38 Piriformis M...

Med Sci Monit In Press; DOI: 10.12659/MSM.943720  

0:00

05 Apr 2024 : Clinical Research  

Comparative Analysis of Transoral Endoscopic Parathyroidectomy Vestibular Approach and Focused Open Surgery...

Med Sci Monit In Press; DOI: 10.12659/MSM.944128  

05 Mar 2024 : Clinical Research  

Muscular Function Recovery from General Anesthesia in 132 Patients Undergoing Surgery with Acceleromyograph...

Med Sci Monit In Press; DOI: 10.12659/MSM.942780  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750